Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23385568 | 0.85 | NLRP3 (0.41) | NLRP3CA2 | |
| SCHEMBL24806328 | 0.85 | NLRP3 (0.38) | NLRP3CA2 | |
| SCHEMBL18029693 | 0.81 | NLRP3 (0.55) | NLRP3CA2 | |
| SCHEMBL19871704 | 0.77 | NLRP3 (0.55) | NLRP3CA2 | |
| SCHEMBL22012922 | 0.76 | PSEN1 (0.32) | NLRP3 | |
| SCHEMBL18029662 | 0.76 | NLRP3 (0.57) | NLRP3CA2 | |
| SCHEMBL19869317 | 0.76 | NLRP3 (0.60) | NLRP3CA2 | |
| SCHEMBL30694066 | 0.75 | CA2 (0.39) | NLRP3CA2 | |
| SCHEMBL19506100 | 0.75 | NLRP3 (0.46) | NLRP3CA2 | |
| SCHEMBL6869002 | 0.74 | NLRP3 (0.45) | NLRP3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635373-B | Amide derivatives and use thereof | 康百达（四川）生物医药科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-116635374-B | Amide derivatives and use thereof | 康百达（四川）生物医药科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-11976054-B2 | Amide derivative and preparation method therefore and use thereof in medicine | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-05-07 | — | — | US | disclosed |
| CN-117105890-A | Amide derivative, preparation method thereof and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116917282-A | Amide derivatives and use thereof | 成都百裕制药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116635373-A | Amide derivatives and use thereof | 成都百裕制药股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116635374-A | Amide derivatives and use thereof | 成都百裕制药股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20220411392-A1 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| WO-2022237781-A1 | AMIDE DERIVATIVE AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237780-A1 | AMIDE DERIVATIVE AND USE THEREOF | 成都百裕制药股份有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237782-A1 | AMIDE DERIVATIVE AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2022-11-17 | — | — | WO | disclosed |
| EP-4059930-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-09-21 | — | — | EP | disclosed |
| EP-3914585-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| CN-113329998-A | Sulfonimidyl amide compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-112851607-A | Amide derivative, preparation method and medical application thereof | 成都百裕制药股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021093820-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2021093820-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2020154499-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976054-B2 | Amide derivative and preparation method therefore and use thereof in medicine | NLRP3, NLRP1, PYCARD | NLRP3 1/4885CA2 2031/4885 |
| US-20220411392-A1 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | NLRP3, NLRP1, PYCARD | NLRP3 1/4885CA2 2031/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885CA2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.